{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:08:23Z","timestamp":1790467703614,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.107021","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:28:56Z","timestamp":1768714136000},"page":"107021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Low prevalence of inflammatory bowel disease among patients with seropositive neuromyelitis optica spectrum disorder in two large referral centers"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-6795","authenticated-orcid":false,"given":"Carolyn","family":"Akers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Bilodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia Wruble","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taymour","family":"Hashemzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamik","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-949X","authenticated-orcid":false,"given":"Ilya","family":"Kister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107021_bib0001","article-title":"Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2026.107021_bib0002","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70214","article-title":"Comorbidities are associated with unfavorable outcome in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: exploratory study from the CROCTINO cohort","volume":"32","author":"Samadzadeh","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107021_bib0003","first-page":"132","article-title":"Multiple autoimmune syndrome","volume":"5","author":"Cojocaru","year":"2010","journal-title":"Maedica"},{"issue":"6","key":"10.1016\/j.msard.2026.107021_bib0004","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production","volume":"142","author":"Cotzomi","year":"2019","journal-title":"Brain J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107021_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178722","article-title":"Estimation of prevalence of autoimmune diseases in the United States using electronic health record data","volume":"135","author":"Abend","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2026.107021_bib0006","first-page":"81","article-title":"The prevalence of inflammatory bowel disease (IBD) in patients with multiple sclerosis (MS): a systematic review and meta-analysis","volume":"14","author":"Nasirzadeh","year":"2023","journal-title":"Int. J. Prev. Med."},{"issue":"2","key":"10.1016\/j.msard.2026.107021_bib0007","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00415-016-8340-8","article-title":"Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis","volume":"264","author":"Kosmidou","year":"2017","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107021_bib0008","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.51495","article-title":"Multiple sclerosis and inflammatory bowel disease: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107021_bib0009","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2009.199679","article-title":"New IBD genetics: common pathways with other diseases","volume":"60","author":"Lees","year":"2011","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.msard.2026.107021_bib0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non\u2013Organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107021_bib0011","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.mayocp.2024.11.028","article-title":"Risk of autoimmune rheumatic diseases in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide cohort study in South Korea","volume":"100","author":"Kwon","year":"2025","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.msard.2026.107021_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.msard.2026.107021_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105683","article-title":"Impact of comorbidities on relapsing rates of Neuromyelitis Optica Spectrum Disorders: insights from a longitudinal study in Taiwan","volume":"87","author":"Hsu","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2026.107021_bib0014","first-page":"1731","article-title":"Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases","volume":"44","author":"Carnero Contentti","year":"2023","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"issue":"1","key":"10.1016\/j.msard.2026.107021_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/00365521.2020.1854847","article-title":"Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018","volume":"56","author":"Kristj\u00e1nsson","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.msard.2026.107021_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578446","article-title":"Spectrum of auto-antibodies in NMO and MOG associated CNS demyelination- the SANMAD study","volume":"396","author":"Samim","year":"2024","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107021_bib0017","article-title":"Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a systematic review","volume":"8","author":"Molazadeh","year":"2022","journal-title":"Mult. Scler. J. \u2013 Exp. Transl. Clin."},{"issue":"2","key":"10.1016\/j.msard.2026.107021_bib0018","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2026.107021_bib0019","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107021_bib0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fneur.2020.00632","article-title":"Harnessing real-world data to inform decision-making: multiple sclerosis partners advancing technology and health solutions (MS PATHS)","volume":"11","author":"Mowry","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107021_bib0021","article-title":"The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107021_bib0022","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00441-004-0932-4","article-title":"Aquaporin expression is downregulated in a murine model of colitis and in patients with ulcerative colitis, Crohn\u2019s disease and infectious colitis","volume":"318","author":"Hardin","year":"2004","journal-title":"Cell Tissue Res."},{"issue":"2","key":"10.1016\/j.msard.2026.107021_bib0023","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107021_bib0024","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1084\/jem.20140540","article-title":"VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells","volume":"211","author":"Schneider-Hohendorf","year":"2014","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.msard.2026.107021_bib0025","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2026.107021_bib0026","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jneuroim.2004.11.017","article-title":"Interferon-beta-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis","volume":"161","author":"Graber","year":"2005","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.msard.2026.107021_bib0027","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/brain\/awad373","article-title":"Interferon-\u03b3 controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder","volume":"147","author":"Arellano","year":"2024","journal-title":"Brain J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107021_bib0028","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1172\/JCI124884","article-title":"IFN-\u03b3 drives inflammatory bowel disease pathogenesis through VE-cadherin\u2013directed vascular barrier disruption","volume":"129","author":"Langer","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2026.107021_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106719","article-title":"Neuromyelitis optica spectrum disorders and their overlap with myasthenia gravis in a single center in Argentina","volume":"103","author":"Villa","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107021_bib0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28006","article-title":"Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis","volume":"69","author":"Rodrigues","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.msard.2026.107021_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819827692","article-title":"Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010","volume":"12","author":"Aniwan","year":"2019","journal-title":"Therap. Adv. Gastroenterol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:54:52Z","timestamp":1780415692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S221103482600057X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107021","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low prevalence of inflammatory bowel disease among patients with seropositive neuromyelitis optica spectrum disorder in two large referral centers","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107021"}}